Cerebrospinal fluid/serum albumin quotient (Q-Alb) is not increased in Alzheimer's disease compared to neurological disease controls: a retrospective study on 276 patients.
Albumin quotient (Q-Alb)
Alzheimer’s disease (AD)
Blood-brain barrier (BBB)
Blood-cerebrospinal fluid barrier (BCSFB)
Cerebrospinal fluid (CSF)
Journal
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
received:
01
11
2022
accepted:
22
11
2022
pubmed:
29
11
2022
medline:
19
1
2023
entrez:
28
11
2022
Statut:
ppublish
Résumé
The cerebrospinal fluid (CSF)/serum albumin quotient (Q-Alb) is a marker of the blood-CSF barrier (BCSFB) and possibly of the blood-brain barrier (BBB). The latter is known to be altered in Alzheimer's disease (AD) based on neuropathological and neuroimaging studies. Following investigations performed on clinically diagnosed cohorts, we aimed at comparing Q-Alb in cognitively impaired patients with neurochemical demonstration of AD pathophysiology and neurological disease controls (NDCs). We evaluated N = 144 AD patients (MCI, N = 43; AD dementia - ADD, N = 101) and N = 132 NDCs. AD patients were all A + according to the A/T/N framework and were neurochemically classified based on T and N parameters. Q-Alb did not significantly differ between AD patients and NDCs. Moreover, it was not associated with disease stage (MCI vs. ADD), MMSE score, or CSF AD biomarkers. Our study indicates that BCSFB dysfunction is not a specific feature of AD. When interpreting Q-Alb as a marker of the BBB, the lack of difference from NDCs might be due to BBB dysfunction widely occurring in other neurological, non-degenerative, conditions or - more probably - to low sensitivity of this biochemical parameter towards subtle BBB alterations causing leakage of molecules smaller than albumin. Furthermore, Q-Alb is not associated with the degree of global cognitive deterioration in AD, nor with CSF AD neurochemical biomarkers.
Sections du résumé
BACKGROUND
BACKGROUND
The cerebrospinal fluid (CSF)/serum albumin quotient (Q-Alb) is a marker of the blood-CSF barrier (BCSFB) and possibly of the blood-brain barrier (BBB). The latter is known to be altered in Alzheimer's disease (AD) based on neuropathological and neuroimaging studies. Following investigations performed on clinically diagnosed cohorts, we aimed at comparing Q-Alb in cognitively impaired patients with neurochemical demonstration of AD pathophysiology and neurological disease controls (NDCs).
METHODS
METHODS
We evaluated N = 144 AD patients (MCI, N = 43; AD dementia - ADD, N = 101) and N = 132 NDCs. AD patients were all A + according to the A/T/N framework and were neurochemically classified based on T and N parameters.
RESULTS
RESULTS
Q-Alb did not significantly differ between AD patients and NDCs. Moreover, it was not associated with disease stage (MCI vs. ADD), MMSE score, or CSF AD biomarkers.
DISCUSSION
CONCLUSIONS
Our study indicates that BCSFB dysfunction is not a specific feature of AD. When interpreting Q-Alb as a marker of the BBB, the lack of difference from NDCs might be due to BBB dysfunction widely occurring in other neurological, non-degenerative, conditions or - more probably - to low sensitivity of this biochemical parameter towards subtle BBB alterations causing leakage of molecules smaller than albumin. Furthermore, Q-Alb is not associated with the degree of global cognitive deterioration in AD, nor with CSF AD neurochemical biomarkers.
Identifiants
pubmed: 36441343
doi: 10.1007/s10072-022-06530-w
pii: 10.1007/s10072-022-06530-w
doi:
Substances chimiques
Amyloid beta-Peptides
0
Biomarkers
0
Serum Albumin
0
tau Proteins
0
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
709-713Subventions
Organisme : Ministero della Salute
ID : GR-2016-02364373
Informations de copyright
© 2022. Fondazione Società Italiana di Neurologia.
Références
Hegen H, Auer M, Zeileis A, Deisenhammer F (2016) Upper reference limits for cerebrospinal fluid total protein and albumin quotient based on a large cohort of control patients: implications for increased clinical specificity. Clin Chem Lab Med 54(2):285–292. https://doi.org/10.1515/cclm-2015-0253
doi: 10.1515/cclm-2015-0253
Skillback T, Delsing L, Synnergren J et al (2017) CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients. Neurobiol Aging 59:1–9. https://doi.org/10.1016/j.neurobiolaging.2017.06.028
doi: 10.1016/j.neurobiolaging.2017.06.028
Sweeney MD, Sagare AP, Zlokovic BV (2018) Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol 14(3):133–150. https://doi.org/10.1038/nrneurol.2017.188
doi: 10.1038/nrneurol.2017.188
Janelidze S, Hertze J, Nagga K et al (2017) Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype. Neurobiol Aging 51:104–112. https://doi.org/10.1016/j.neurobiolaging.2016.11.017
doi: 10.1016/j.neurobiolaging.2016.11.017
Musaeus CS, Gleerup HS, Hogh P, Waldemar G, Hasselbalch SG, Simonsen AH (2020) Cerebrospinal fluid/plasma albumin ratio as a biomarker for blood-brain barrier impairment across neurodegenerative dementias. J Alzheimers Dis 75(2):429–436. https://doi.org/10.3233/JAD-200168
doi: 10.3233/JAD-200168
Chalbot S, Zetterberg H, Blennow K et al (2011) Blood-cerebrospinal fluid barrier permeability in Alzheimer’s disease. J Alzheimers Dis 25(3):505–515. https://doi.org/10.3233/JAD-2011-101959
doi: 10.3233/JAD-2011-101959
Lin Z, Sur S, Liu P et al (2021) Blood-brain barrier breakdown in relationship to Alzheimer and vascular disease. Ann Neurol 90(2):227–238. https://doi.org/10.1002/ana.26134
doi: 10.1002/ana.26134
Jack CR Jr, Bennett DA, Blennow K et al (2018) NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement 14(4):535–562. https://doi.org/10.1016/j.jalz.2018.02.018
doi: 10.1016/j.jalz.2018.02.018
Sjogren M, Vanderstichele H, Agren H et al (2001) Tau and Abeta42 in cerebrospinal fluid from healthy adults 21–93 years of age: establishment of reference values. Clin Chem 47(10):1776–1781
doi: 10.1093/clinchem/47.10.1776
Gobom J, Parnetti L, Rosa-Neto P et al (2022) Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. Clin Chem Lab Med 60(2):207–219. https://doi.org/10.1515/cclm-2021-0651
doi: 10.1515/cclm-2021-0651